Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01506323 · ClinicalTrials.gov registry record · Phase 3
Mantram Repetition Meditation for Veterans With PTSD
A Phase 3 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 181
- Enrollment target
NCT01506323: Completed Phase 3 study, sponsored by US Department of Veterans Affairs.
NCT01506323 is a Phase 3 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 181 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01506323, a Phase 3 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 181 participants
- Enrollment target
Study Summary
The aim of this study was to determine the usefulness of a portable, meditation-based intervention called the Mantram Repetition Program (MRP) for Veterans with military-related posttraumatic stress disorder (PTSD). This study compared the individual delivery of the MRP to individual delivery of Present-Centered Therapy (PCT) at two sites in San Diego, California, and Bedford, Massachusetts.
Primary Outcome
PTSD symptom severity is measured by CAPS to determine PTSD diagnosis. The scale rates 17 items representing the Diagnostic and Statistical Manual IV (DSM-IV) criteria B (re-experiencing), C (avoidance/numbing) and D (hyper-arousal). CAPS has demonstrated high levels of internal consistency, good inter-rater reliability, \& excellent convergent validity. The F1/I2 rule will be applied to establish the diagnosis of PTSD aligned with DSM-IV (e.g. one symptom of Criterion B, three of Criterion C, a
Interventions
- BEHAVIORAL Mantram Repetition Program (MRP)
- BEHAVIORAL Present Centered Therapy (PCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
What the finished NCT01506323 record still lists
NCT01506323 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Mantram Repetition Program (MRP) is the first listed.
NCT01506323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01506323 about?
NCT01506323 is a clinical study titled "Mantram Repetition Meditation for Veterans With PTSD". The aim of this study was to determine the usefulness of a portable, meditation-based intervention called the Mantram Repetition Program (MRP) for Veterans with military-related posttraumatic stress disorder (PTSD). This study compared the individual delivery of the MRP to individual delivery of Pre...
What is the current status of trial NCT01506323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 181 participants. The study started on 2012-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01506323?
The interventions under investigation include: Mantram Repetition Program (MRP) (BEHAVIORAL), Present Centered Therapy (PCT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT01506323?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01506323's enrollment target sits among peer trials
181 1422nd of 2000 higher than 579 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia